Home
May 2010 Volume 34 No. 5

From the April meeting
of the SHC Pharmacy and Therapeutics Committee.
For further information, contact Dana Radman, pharmacy manager and committee secretary, DRadman@stanfordmed.org.

ADDED TO FORMULARY

Recombinant human hyaluronidase injection (Hylenex™), indicated for hypodermoclysis (facilitates subcutaneous parenteral fluid therapy to achieve hydration)

Proposed efficacy monitoring
- Assessment of adequate rehydration

Proposed safety monitoring
- Monitor for accurate placement of the subcutaneous catheter and infusion site reactions such as pain, tenderness, erythema and rash.

DELETED FROM FORMULARY

Drotrecogin alfa (Xigris®) and animal-derived hyaluronidase products (Vitrase® and Amphadase™)

The Pharmacy Department now has an intranet site.
Find contact information, how to add a drug to the formulary, guidelines and reference cards: http://portal.stanfordmed.org/depts/pharmacy/default.aspx